Document is current
Any future updates will be listed below
-
Authors
Schwaneck, Eva C. https://orcid.org/0000-0003-1935-2092
Harasim, Anna S. https://orcid.org/0000-0002-2866-9481
Tony, Hans-Peter
Gawlik, Micha
Witte, Torsten https://orcid.org/0000-0003-4531-0267
Joos, Stefanie https://orcid.org/0000-0002-5810-529X
Gernert, Michael https://orcid.org/0000-0003-0074-4459
Schmalzing, Marc
Morbach, Henner https://orcid.org/0000-0002-5819-726X
Fröhlich, Matthias https://orcid.org/0000-0001-7745-3903
Krone, Manuel https://orcid.org/0000-0002-1020-6454
- License Information
-
More Information
Article History
Accepted: 1 July 2024
First Online: 22 August 2024
Declarations
:
: H.-P. Tony has received honoraria for consultation, travel grants, or speaker’s fees from Takeda/Shire, Pfizer, GSK, Sanofi, and MSD. T. Witte has received honoraria for lectures from AstraZeneca, CSL, GSK, Octapharma, Pfizer, Takeda, and CSL Behring. M. Gernert received travel grants from AbbVie, Chugai, Eli Lilly, Hexal, Janssen-Cilag, Novartis, and Pfizer and compensation for board memberships from Takeda. M. Schmalzing has received compensation for consultancies from Chugai/Roche, Hexal/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, medac, and Lilly; speaker’s fees from Novartis, AbbVie, AstraZeneca, Chugai/Roche, Janssen-Cilag, Gilead, and Boehringer/Ingelheim; and travel grants from Chugai/Roche, Boehringer/Ingelheim, Celgene, Medac, UCB, and Mylan. H. Morbach has received honoraria for speaking at symposia from Shire/Takeda and CSL Behring and honoraria for consultation from Shire/Takeda. M. Fröhlich has received financial support for attending symposia from AbbVie, Novartis, Janssen, Lilly, and Roche. E.C. Schwaneck has received honoraria for speaking at symposia, financial support for attending symposia, and research grants and honoraria for consultation from Janssen, Alfasigma, Eli Lilly, Chugai, Roche, Takeda (Shire), AbbVie, Novartis, Pfizer, Otsuka, Medac, Boehringer Ingelheim, Astra Zeneca, and Fresenius. M. Krone has received honoraria for consultation from Abbott, GlaxoSmithKline, Pfizer, and Sanofi outside the submitted work. A.S. Harasim, M. Gawlik, and S. Joos declare that they have no competing interests.
: Approval was obtained from the ethics committees of the University of Würzburg (file number 147/18-sc) and the University of Hanover (file number 8279_BO_K_2019). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.
